Features of mono regimen oral gestagen contraceptives
https://doi.org/10.14341/brh12786
Abstract
The present review contains information about features and effects of oral contraceptives containing 75 mcg of desogestrel. Oral contraceptive pills containing 75 mcg of desogestrel are safe for mothers and babies on breastfeeding. Oral contraceptive pills containing 75 mcg of desogestrel. Progestogen-only pills containing 75 mcg of desogestrel ("mini pills") are reliable and safe for contraception among patients with high risk of venous and arterial thrombosis, contraindications for estrogenes, smoking addiction, high metabolic risks (obesity, diabetes mellitus type 2) including females 45 years old and older.
About the Authors
A. F. VesninaRussian Federation
Anna F. Vesnina - PhD.
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
none
E. N. Andreeva
Russian Federation
Elena N. Andreeva - MD, PhD, Professor.
Moscow
Competing Interests:
none
References
1. Genazzani AR, Fidecicchi T, Arduini D, Giannini A, Simoncini T. Hormonal and natural contraceptives: a review on efficacy and risks of different methods for an informed choice. Gynecol Endocrinol. 2023;39(1):2247093. doi: https://doi.org/10.1080/09513590.2023.2247093
2. Conde-Agudelo A, Belizán JM, Norton MH, Rosas-Bermúdez A. Effect of the interpregnancy interval on perinatal outcomes in Latin America. Obstet Gynecol. 2005;106(2):359–66
3. Wang Y, Zeng C, Chen Y, Yang L, Tian D, Liu X, Lin Y. Short interpregnancy interval can lead to adverse pregnancy outcomes: A meta-analysis. Front Med (Lausanne). 2022;9:922053. doi: https://doi.org/10.3389/fmed.2022.922053
4. Yelgina SI, Kadashnikova KV, Migulko DA, Tretyakova SV, Moses VG, Rudaeva EV, Moses KV. The relevance of observing the intergenetic interval. Mother and Child in Kuzbass. 2022;3(90):161-163 (In Russ.)
5. Mason E, Black K. Update on long- and short-acting contraceptive methods. Aust Prescr. 2025;48(3):72-81. doi: https://doi.org/10.18773/austprescr.2025.023
6. Westerfield KL, Koenig K, Oh R. Breastfeeding: Common Questions and Answers. Am Fam Physician. 2018;98(6):368-373
7. Nazarova NM, Prilepskaya VN, Nekrasova ME. Postpartum contraception: efficacy and safety. Gynecology. 2018;2. (In Russ.)
8. Guidelines for Endocrine Gynecology / Edited by E. M. Vikhlyaeva. Moscow: MIA, 2000. 768 с (In Russ.)
9. Chowdhury R, Sinha B, Sankar MJ, Taneja S, Bhandari N, Rollins N, Bahl R, Martines J. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr. 2015;104(467):96-113. doi: https://doi.org/10.1111/apa.13102
10. Kotani M, Katagiri F, Hirai T, Kagawa J, Tanaka I. Plasma kisspeptin levels in lactational amenorrhea. Gynecol Endocrinol. 2017;33(10):819-821. doi: https://doi.org/10.1080/09513590.2017.1320380
11. Dobrokhotova YuE, Borovkova EI, Zalesskaya SA. Progesterone-containing contraceptives: a place in practical gynecology (to help a practicing physician). Gynecology. 2018;20(3):48-51. (In Russ.) doi: https://doi.org/10.26442/2079-5696_2018.3.48-51
12. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception. 2016;94(3):226–52
13. Sridhar A, Salcedo J. Optimizing maternal and neonatal outcomes with postpartum contraception: impact on breastfeeding and birth spacing. Matern Health Neonatol Perinatol. 2017;3:1. Published 2017 Jan 13. doi:10.1186/s40748-016-0040-y
14. General characteristics of the drug DESERIA® 75 mcg, tablets, LP-No.(008669)-(RG-RU)-030225 (In Russ.) https://pharma.eaeunion.org/pharma/registers/26/ru/register/registered-medicinal-products/65c5ff5930dcf8482095c5f8
15. Epishkina-minina AA, Khamoshina MB, Grabovsky VM, Startseva NM, Papysheva OV, Kostin IN. Gestational diabetes mellitus: current status problems. Obstetrics and gynecology: News. Opinions. Training. 2018. Appendix 3 (In Russ.)
16. Demidova TYu, Ushanova FO. Pathophysiological aspects of the development of gestational diabetes mellitus. breast cancer. Medical review. 2019;3(10(II)):86-91. (In Russ.)
17. Мурашко М.А. материалы доклада XXXI Российский национальный конгресс «Человек и лекарство» 15–18 апреля 2024 г. [Murashko MA. Materials of the XXXI Russian National Congress "Man and Medicine" report on April 15-18, 2024. (In Russ.)]
18. Belail Hammad WA, Gupta N, Konje JC. An overview of contraception in women with obesity. Best Pract Res Clin Obstet Gynaecol. 2023;91:102408. doi: https://doi.org/10.1016/j.bpobgyn.2023.102408
19. Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016;2016(8):CD008452. doi: https://doi.org/10.1002/14651858.CD008452
20. Vogel B, Acevedo M, Appelman Y, et al. The lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet Commiss. 2021;397(10292):2385–2438
21. Napolitano A, Zanin R, Palma F, Romani C, Grandi G, Di Carlo C, Cagnacci A. Body composition and resting metabolic rate of perimenopausal women using continuous progestogen contraception. The European Journal of Contraception & Reproductive Health Care. 2015;21(2):168–175. doi: https://doi.org/10.3109/13625187.2015.1079610
22. Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32(9):749-751. doi: https://doi.org/10.3109/09513590.2016.1161743
23. Zuniga C, Blanchard K, Harper CC, Wollum A, Key K, Henderson JT. Effectiveness and efficacy rates of progestin-only pills: A comprehensive literature review. Contraception. 2023;119:109925. doi: https://doi.org/10.1016/j.contraception.2022.109925
24. Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Front Endocrinol (Lausanne). 2021;12:769187. doi: https://doi.org/10.3389/fendo.2021.769187
25. Alshurafa A, Benkhadra M, Babiker AM, Mohammed WM, Yassin MA. Contraception in Myeloproliferative Neoplasms: A Pharmacological Review. Eur J Haematol. 2025;115(4):344-348. doi: https://doi.org/10.1111/ejh.70014
26. National medical criteria for the acceptability of contraceptive methods Adapted document "WHO Medical criteria for the acceptability of contraceptive methods, 5th edition, 2015" Moscow 2023 (In Russ.)
27. Regidor PA, Colli E. The progestin-only pills drospirenone 4 mg and desogestrel 0.075 mg as an option for the management of dysmenorrhea and mastodynia. Gynecological Endocrinology. 2022;38(11):978–982. doi: https://doi.org/10.1080/09513590.2022.2134339
28. Vannuccini S, La Torre F, Toscano F, Speciale AR, Giani M, Tureli D, Petraglia F. Medical treatment for adenomyosis: long term use of progestins. Gynecological Endocrinology. 2025:41(1). doi: https://doi.org/10.1080/09513590.2025.2511329
29. Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016;93(4):303-309. doi: https://doi.org/10.1016/j.contraception.2015.12.007
30. An expert report on the assessment of safety, effectiveness and quality. Review of DESERIUM (INN desogestrel), dated 30.01.2025 (In Russ.) https://pharma.eaeunion.org/pharma/registers/26/ru/register/registered-medicinal-products/65c5ff5930dcf8482095c5f8
31. Clinical guidelines for Contraception. Monitoring the use of contraceptives.2024 (In Russ.)
Review
For citations:
Vesnina A.F., Andreeva E.N. Features of mono regimen oral gestagen contraceptives. Bulletin of Reproductive Health. 2026;(1):32-39. (In Russ.) https://doi.org/10.14341/brh12786
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).















